The limited clinical value of a specific diabetic cardiomyopathy

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 7, 2013, Pages 599-605

  Vigili de Kreutzenberg, S ^a   Avogaro, A ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Cardiomyopathy; Diabetes; Heart failure

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; GLITAZONE DERIVATIVE; IRBESARTAN; LOSARTAN;

ANIMAL; BLOOD; BLOOD PRESSURE; CARDIOGRAPHY; CARDIOVASCULAR RISK; CLINICAL FEATURE; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DISEASE PREDISPOSITION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HISTOLOGY; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN TREATMENT; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WORLD HEALTH ORGANIZATION;

ANIMALIA;

EID: 84884700524     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2013.03.008     Document Type: Review

References (83)

1. Nolan C., Damm P., Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011, 378:169-181.
2. [accessed 05.01.13]. http://www.diabetes.org/diabetes-basics/diabetes-statistics/.
3. Diabetes mellitus, fasting glucose, and risk of cause-specific death. The Emerging Risk Factors Collaboration. N Engl J Med 2011, 364:829-841.
4. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study. J Am Med Assoc 1979, 241(19):2035-2038.
5. Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972, 30(6):595-602.
6. Galderisi M., Anderson K.M., Wilson P.W., Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991, 68(1):85-89.
7. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996, 93:841-842.
8. Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005, 85(3):1093-1129.
9. Boudina S., Abel E.D. Diabetic cardiomyopathy revisited. Circulation 2007, 115(25):3213-3223.
10. Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000, 86(5):580-588.
11. Fragasso G., Palloshi A., Puccetti P., Silipigni C., Rossodivita A., Pala M., et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006, 48(5):992-998.
12. Lopaschuk G.D., Ussher J.R., Folmes C.D., Jaswal J.S., Stanley W.C. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010, 90(1):207-258.
13. Reagan T.J., Lyons M.M., Ahmed S.S., Levinson G.E., Oldewurtel H.A., Ahmad M.R., et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977, 60(4):884-899.
14. McGavock J.M., Lingvay I., Zib I., Tillery T., Salas N., Unger R., et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007, 116(10):1170-1175.
15. Rijzewijk L.J., van der Meer R.W., Smit J.W., Diamant M., Bax J.J., Hammer S., et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008, 52:1793-1799.
16. van der Meer R.W., Rijzewijk L.J., de Jong H.W., Lamb H.J., Lubberink M., Romijn J.A., et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 2009, 119(15):2069-2077.
17. Ng A.C., Delgado V., Bertini M., van der Meer R.W., Rijzewijk L.J., Hooi Ewe S., et al. Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation 2010, 122(24):2538-2544.
18. Cai L., Li W., Wang G., Guo L., Jiang Y., Kang Y.J. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome c-mediated caspase-3 activation pathway. Diabetes 2002, 51:1938-1948.
19. Duncan J.G. Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta 2011, 1813(7):1351-1359.
20. Asghar O., Al-Sunni A., Khavandi K., Khavandi A., Withers S., Greenstein A., et al. Diabetic cardiomyopathy. Clin Sci (Lond) 2009, 116(10):741-760.
21. Watanabe K., Thandavarayan R.A., Harima M., Sari F.R., Gurusamy N., Veeraveedu P.T., et al. Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy. Curr Cardiol Rev 2010, 6(4):280-290.
22. Cai L., Kang Y.J. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 2001, 1(3):181-193.
23. Fang Z.Y., Prins J.B., Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004, 25:543-567.
24. Boudina S., Abel E.D. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 2010, 11:31-39.
25. Avogaro A., Vigili de Kreutzenberg S., Negut C., Tiengo A., Scognamiglio R. Diabetic cardiomyopathy: a metabolic perspective. Am J Cardiol 2004, 93(8A):13A-16A.
26. Li Z., Zhang T., Dai H., Liu G., Wang H., Sun Y., et al. Involvement of endoplasmic reticulum stress in myocardial apoptosis of streptozocininduced diabetic rats. J Clin Biochem Nutr 2007, 41:58-67.
27. English A.R., Zurek N., Voeltz G.K. Peripheral ER structure and function. Curr Opin Cell Biol 2009, 21(4):596-602.
28. Xu J., Zhou Q., Xu W., Cai L. Endoplasmic reticulum stress and diabetic cardiomyopathy. Exp Diabetes Res 2012, 2012:827971.
29. Younce C.W., Wang K., Kolattukudy P.E. Hyperglycaemia-induced cardiomyocyte death is mediated via MCP-1 production and induction of a novel zinc-finger protein MCPIP. Cardiovasc Res 2010, 87:665-674.
30. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
31. Yan S.F., Ramasamy R., Naka Y., Schmidt A.M. Glycation, inflammation, and RAGE. A scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003, 93:1159-1169.
32. Lim H.S., MacFadyen R.J., Lip G.Y. Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. Arch Intern Med 2004, 164(16):1737-1748.
33. Linthout S.V., Spillmann F., Schultheiss H.P., Tschöpe C. Effects of mesenchymal stromal cells on diabetic cardiomyopathy. Curr Pharm Des 2011, 17(30):3341-3347.
34. Singh G.B., Sharma R., Khullar M. Epigenetics and diabetic cardiomyopathy. Diabetes Res Clin Pract 2011, 94(1):14-21.
35. Factor S.M., Borczuk A., Charron M.J., Fein F.S., van Hoeven K.H., Sonnenblick E.H. Myocardial alterations in diabetes and hypertension. Diabetes Res Clin Pract 1996, 31(Suppl.):S133-S142.
36. Jouven X., Lemaitre R.N., Rea T.D., Sotoodehnia N., Empana J.P., Siscovick D.S. Diabetes, glucose level, and risk of sudden cardiac death. Eur Heart J 2005, 26(20):2142-2147.
37. From A.M., Leibson C.L., Bursi F., Redfield M.M., Weston S.A., Jacobsen S.J., et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med 2006, 119(7):591-599.
38. Nichols G.A., Gullion C.M., Koro C.E., Ephross S.A., Brown J.B. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004, 27(8):1879-1884.
39. Devereux R.B., Roman M.J., Paranicas M., O'Grady M.J., Lee E.T., Welty T.K., et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation 2000, 101(19):2271-2276.
40. de Simone G., Devereux R.B., Roman M.J., Chinali M., Barac A., Panza J.A., et al. Does cardiovascular phenotype explain the association between diabetes and incident heart failure? the Strong Heart Study. Nutr Metab Cardiovasc Dis 2013, 23(4):285-291.
41. Konduracka E., Gackowski A., Rostoff P., Galicka-Latala D., Frasik W., Piwowarska W. Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. Eur Heart J 2007, 28(20):2465-2471.
42. Maisch B., Alter P., Pankuweit S. Diabetic cardiomyopathy-fact or fiction?. Herz 2001, 36:102-115.
43. Zarich S.W., Arbuckle B.E., Cohen L.R., Roberts M., Nesto R.W. Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol 1988, 12(1):114-120.
44. Nagueh S.F., Appleton C.P., Gillebert T.C., Marino P.N., Oh J.K., Smiseth O.A., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009, 22(2):107-133.
45. Ernande L., Bergerot C., Rietzschel E.R., De Buyzere M.L., Thibault H., Pignonblanc P.G., et al. Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy?. J Am Soc Echocardiogr 2011, 24(11):1268-1275.
46. Ng A.C.T., Delgado V., Bertini M., van der Meer R.W., Rijzewijk L.J., Shanks M., et al. Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol 2009, 104:1398-1401.
47. Ernande L., Rietzschel E.R., Bergerot C., De Buyzere M.L., Schnell F., Groisne L., et al. Impaired myocardial radial function in asymptomatic patients with type 2 diabetes mellitus: a speckle-tracking imaging study. J Am Soc Echocardiogr 2010, 23:1266-1272.
48. Cioffi G., Giorda C.B., Chinali M., Di Lenarda A., Faggiano P., Lucci D., et al. Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study. Eur J Prev Cardiol 2012, 19(5):935-943.
49. Shah P., Choi B.G., Mazhari R. Positron emission tomography for the evaluation and treatment of cardiomyopathy. Ann N Y Acad Sci 2011, 1228:137-149.
50. Shivu G.N., Abozguia K., Phan T.T., Ahmed I., Weaver R., Narendran P., et al. Increased left ventricular torsion in uncomplicated type 1 diabetic patients: the role of coronary microvascular function. Diabetes Care 2009, 32(9):1710-1712.
51. Yonaha O., Matsubara T., Naruse K., Ishii H., Murohara T., Nakamura J., et al. Effects of reduced coronary flow reserve on left ventricular function in type 2 diabetes. Diabetes Res Clin Pract 2008, 82(1):98-103.
52. Maya L., Villarreal F.J. Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis. J Mol Cell Cardiol 2010, 48(3):524-529.
53. Rijzewijk L.J., van der Meer R.W., Lamb H.J., de Jong H.W., Lubberink M., Romijn J.A., et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 2009, 54(16):1524-1532.
54. Romano S., Di Mauro M., Fratini S., Guarracini L., Guarracini F., Poccia G., et al. Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides. Cardiovasc Diabetol 2010, 9:89-95.
55. Fang Z.Y., Schull-Meade R., Leano R., Mottram P.M., Prins J.B., Marwick T.H. Screening for heart disease in diabetic subjects. Am Heart J 2005, 149(2):349-354.
56. Govind S., Saha S., Brodin L.A., Ramesh S.S., Arvind S.R., Quintana M. Impaired myocardial functional reserve in hypertension and diabetes mellitus without coronary artery disease: searching for the possible link with congestive heart failure in the myocardial Doppler in diabetes (MYDID) study II. Am J Hypertens 2006, 19(8):851-857.
57. Adler A.I., Stratton I.M., Neil H.A., Yudkin J.S., Matthews D.R., Cull C.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000, 321(7258):412-419.
58. Carr A.A., Kowey P.R., Devereux R.B., Brenner B.M., Dahlöf B., Ibsen H., et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 2005, 96(11):1530-1536.
59. Preiss D., Zetterstrand S., McMurray J.J., Ostergren J., Michelson E.L., Granger C.B., et al. Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Investigators. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care 2009, 32(5):915-920.
60. Berl T., Hunsicker L.G., Lewis J.B., Pfeffer M.A., Porush J.G., Rouleau J.L., et al. Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003, 138(7):542-549.
61. Nichols G.A., Hillier T.A., Erbey J.R., Brown J.B. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001, 24(9):1614-1619.
62. Vaur L., Gueret P., Lievre M., Chabaud S., Passa P. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care 2003, 26(3):855-860.
63. Pazin-Filho A., Kottgen A., Bertoni A.G., Russell S.D., Selvin E., Rosamond W.D., et al. HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 2008, 51(12):2197-2204.
64. Gottdiener J.S., Arnold A.M., Aurigemma G.P., Polak J.F., Tracy R.P., Kitzman D.W., et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000, 35(6):1628-1637.
65. de Simone G., Devereux R.B., Chinali M., Lee E.T., Galloway J.M., Barac A., et al. Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. J Hypertens 2010, 28(2):353-360.
66. Cicala S., de Simone G., Roman M.J., Best L.G., Lee E.T., Wang W., et al. Prevalence and prognostic significance of wall-motion abnormalities in adults without clinically recognized cardiovascular disease: the Strong Heart Study. Circulation 2007, 116(2):143-150.
67. Kenchaiah S., Evans J.C., Levy D., Wilson P.W., Benjamin E.J., Larson M.G., et al. Obesity and the risk of heart failure. N Engl J Med 2002, 347(5):305-313.
68. Loehr L.R., Rosamond W.D., Poole C., McNeill A.M., Chang P.P., Folsom A.R., et al. Association of multiple anthropometrics of overweight and obesity with incident heart failure: the Atherosclerosis Risk in Communities study. Circ Heart Fail 2009, 2(1):18-24.
69. Horwich T.B., Fonarow G.C. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol 2010, 55(4):283-293.
70. Curtis J.P., Selter J.G., Wang Y., Rathore S.S., Jovin I.S., Jadbabaie F., et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005, 165:55-61.
71. Adamopoulos C., Meyer P., Desai R.V., Karatzidou K., Ovalle F., White M., et al. Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. Eur J Heart Fail 2011, 13(2):200-206.
72. Palmieri V., Bella J.N., Arnett D.K., Liu J.E., Oberman A., Schuck M.Y., et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation 2001, 103(1):102-107.
73. Bella J.N., Devereux R.B., Roman M.J., Palmieri V., Liu J.E., Paranicas M., et al. Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in American Indians (the Strong Heart Study). Am J Cardiol 2001, 87(11):1260-1265.
74. Rutter M.K., Parise H., Benjamin E.J., Levy D., Larson M.G., Meigs J.B., et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 2003, 107(3):448-454.
75. Thrainsdottir I.S., Aspelund T., Thorgeirsson G., Gudnason V., Hardarson T., Malmberg K., et al. The association between glucose abnormalities and heart failure in the populationbased Reykjavik study. Diabetes Care 2005, 28:612-616.
76. Iribarren C., Karter A.J., Go A.S., Ferrara A., Liu J.Y., Sidney S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001, 103(22):2668-2673.
77. A randomized trial of therapies for type 2 diabetes and coronary artery disease the BARI 2D Study Group. N Engl J Med 2009, 360:2503-2515.
78. Ray K.K., Seshasai S.R., Wijesuriya S., Sivakumaran R., Nethercott S., Preiss D., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373(9677):1765-1772.
79. Zhang C.Y., Sun A.J., Zhang S.N., Wu C.N., Fu M.Q., Xia G., et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis. Ann Med 2010, 42(4):305-315.
80. Castagno D., Baird-Gunning J., Jhund P.S., Biondi-Zoccai G., MacDonald M.R., Petrie M.C., et al. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J 2011, 162:938-948.e2.
81. Lago R.M., Singh P.P., Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007, 370:1129-1136.
82. Boussageon R., Bejan-Angoulvant T., Saadatian-Elahi M., Lafont S., Bergeonneau C., Kassaï B., et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. Br Med J 2011, 343:d4169-d4180.
83. Eurich D.T., McAlister F.A., Blackburn D.F., Majumdar S.R., Tsuyuki R.T., Varney J., et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Br Med J 2007, 335(7618):497.